https://docs.google.com/viewer?a=v&q=cac...

"Recently, Technosphere/Insulin, an inhalable formula-
tion under development by MannKind Corporation (Valen-
cia, CA), have initiated the Phase III in both Europe and
the US. The Technosphere technology allows to administer
insulin via pulmonary and offers several competitive advan-
tages over other pulmonary drug delivery systems. Recent
studies have been conducted to analyze the lung deposition
and clearance after administration. Their findings showed a
uniform distribution throughout the lungs and absorption
of insulin into the systemic circulation. Based on the results
of clinical trials and on published reports, Technosphere is
better than other inhaled insulin platforms [113]."

[113] S. S. Iyer, W. H. Barr, and H. T. Karnes, “A ’biorelevant’
approach to accelerated in vitro drug release testing of a
biodegradable, naltrexone implant,” International Journal of
Pharmaceutics, vol. 340, no. 1-2, pp. 119–125, 2007.